Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Slides:

Advertisements

Similar presentations

Reduced renal function in patients with simple renal cysts

Advertisements

Volume 59, Issue 3, Pages (March 2001)

Volume 9, Issue 8, Pages (August 2017)

Volume 54, Issue 2, Pages (August 1998)

Volume 64, Issue 4, Pages (October 2003)

Plasma sodium and hypertension

Propofol-related green urine

Sushrut S. Waikar, Venkata S. Sabbisetti, Joseph V. Bonventre

Drug use and nephrotoxicity in the intensive care unit

Anemia management in chronic kidney disease

Volume 82, Issue 12, Pages (December 2012)

Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration.

Volume 61, Issue 4, Pages (April 2002)

Reassessment of the care of the patient with chronic kidney disease

Volume 88, Issue 2, Pages (August 2015)

Hiroyuki Kobori, Lisa M. Harrison-Bernard, L. Gabriel Navar

Better nephrology for mice—and man

Volume 77, Issue 8, Pages (April 2010)

High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury D.P. Gabriel, J.T. Caramori,

Pharmacokinetics of mycophenolic acid in severe lupus nephritis

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Urea for hyponatremia? Kidney International

How to interpret the eGFR in patients with small body surface area

Methotrexate in the urine

Volume 88, Issue 6, Pages (December 2015)

Comorbidity and confounding in end-stage renal disease

Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 81, Issue 3, Pages (February 2012)

Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion Lynda A. Frassetto, Eileen Nash,

Volume 76, Issue 8, Pages (October 2009)

Insulin resistance in African Americans

Renal risk scores: Progress and prospects

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 54, Issue 5, Pages (November 1998)

Volume 77, Issue 2, Pages (January 2010)

Overcorrection of hyponatremia is a medical emergency

Volume 87, Issue 2, Pages (February 2015)

Gentamicin pharmacokinetics during slow daily home hemodialysis

Use of a probioitic to decrease enteric hyperoxaluria

Volume 61, Issue 4, Pages (April 2002)

Volume 76, Issue 6, Pages (September 2009)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Urinary biomarkers: the future looks promising

Volume 74, Issue 8, Pages (October 2008)

Alternate-day dialysis may be needed for hemodialysis patients

Reduced renal function in patients with simple renal cysts

Counteracting progression of renal disease: A look into the future

Volume 78, Issue 11, Pages (December 2010)

Volume 78, Issue 5, Pages (September 2010)

Nephrology Crossword: Glomerulonephritis

Volume 57, Issue 1, Pages (January 2000)

Volume 81, Issue 4, Pages (February 2012)

Volume 64, Issue 1, Pages (July 2003)

Volume 73, Issue 9, Pages (May 2008)

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Phosphate binders on iron basis: A new perspective?

Cystinuria subtype and the risk of nephrolithiasis1

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

The hypothesis that abnormal BH4 metabolism impairs kidney function

Volume 65, Issue 4, Pages (April 2004)

Volume 62, Issue 5, (November 2002)

Aldosterone and potassium secretion by the cortical collecting duct

Volume 77, Issue 12, Pages (June 2010)

Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases Martina Franz, Wolfgang Woloszczuk,

Dose adjustments in patients with CKD are based on the change in the concentration-time profile for the drug of interest. Dose adjustments in patients.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

Presentation transcript:

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh Mallikaarjun Kidney International Volume 85, Issue 4, Pages 953-961 (April 2014) DOI: 10.1038/ki.2013.350 Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 1 Mean (±s.d.) tolvaptan plasma concentration–time profiles by creatinine clearance. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 2 Plots of individual tolvaptan pharmacokinetic parameters versus baseline creatinine clearance (CrCL). AUC∞, area under the curve to infinity; CL/F, clearance; Cmax, maximum plasma concentration; t1/2,z, terminal half-life. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 3 Mean urine excretion rate and free water clearance plotted at the end time of the collection interval at baseline and after tolvaptan dosing. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 4 Mean (±s.d.) daily fluid intake and fluid balance at baseline and change from baseline after tolvaptan dosing. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 5 Mean (±s.d.) daily creatinine clearance at baseline and percent change from baseline after tolvaptan dosing. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 6 Individual values of percent change from baseline in creatinine clearance (CrCL) on days 1 and 2 after tolvaptan dosing. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 7 Mean (±s.d.) change from baseline in serum osmolality, sodium, potassium, and creatinine by creatinine clearance group after tolvaptan dosing. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 8 Mean (±s.d.) daily urinary excretion of osmoles, sodium, and potassium at baseline, and change from baseline after tolvaptan dosing. Kidney International 2014 85, 953-961DOI: (10.1038/ki.2013.350) Copyright © 2014 International Society of Nephrology Terms and Conditions